Bromday approved for post-cataract extraction inflammation and ocular pain reduction
BROMDAY (bromfenac) 0.09% ophthalmic solution by ISTA
The FDA has approved Bromday (bromfenac ophthalmic solution, from ISTA) 0.09%, a nonsteroidal antiinflammatory drug (NSAID), for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction. Bromday is approved for dosing once-daily beginning one day prior to surgery, on the day of surgery and continuing for the first 14 days after surgery.
Bromday is expected to be made available prior to the end of 2010.